Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gelatin + hydroxyethyl starch refers to the combined or sequential administration of two distinct synthetic colloid solutions used for intravascular volume expansion. **Gelatin** is a protein-based colloid, typically succinylated or urea-linked, derived from bovine collagen. **Hydroxyethyl starch (HES)** is a non-ionic starch derivative, often classified by its concentration (e.g., 6%), molecular weight, and substitution ratio (e.g., 130/0.4). Both agents function by increasing the colloid osmotic (oncotic) pressure of the blood, which draws fluid from the interstitial space into the intravascular compartment to restore circulating volume in patients with hypovolemia or shock. However, clinical evidence, including studies in patients with severe sepsis, has demonstrated that these synthetic colloids are associated with a significantly higher incidence of acute renal failure and an increased need for renal replacement therapy compared to crystalloids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gelatin + hydroxyethyl starch.